Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19. …
Latest Video
New Stories
-
Mesoblast says Ryoncil payer coverage extended to over 100 million Americans
April 22, 2025 - - Australian Biotech -
Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial
April 22, 2025 - - Australian Biotech -
Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel
April 22, 2025 - - Australian Biotech -
Race says patient enrolment opened at second site for RC220 solid tumour trial
April 22, 2025 - - Australian Biotech -
Neurizon announces the appointment of chief financial officer
April 22, 2025 - - BioPharmaDispatch Executive -
Australia increasingly isolated after Europe approves Alzheimer's therapy
April 22, 2025 - - BioPharma -
Pharmac proposes three-monthly quantities for popular asthma inhalers
April 22, 2025 - - Latest News